Abstract
Studies of the newer antiepileptic drugs suggest that they are exciting additions with improved efficacy and a perhaps decreased toxicity in certain types of refractory childhood epilepsy. In some very rare syndromes only anecdotal reports exist and further study is needed. Issues of tolerability, long-term safety in very young children, and effects on learning, behavior and other cognitive functions must be balanced with the possibility of improved efficacy. Additional well-controlled studies taking into account both seizure types and epilepsy syndromes are very much needed in neonates, infants, school aged children and adolescents.
MeSH terms
-
Acetates / therapeutic use
-
Adolescent
-
Adult
-
Age Factors
-
Amines*
-
Anticonvulsants / therapeutic use*
-
Carbamazepine / analogs & derivatives
-
Carbamazepine / therapeutic use
-
Child
-
Child, Preschool
-
Clinical Trials as Topic
-
Cyclohexanecarboxylic Acids*
-
Drug Therapy, Combination
-
Epilepsy / drug therapy*
-
Felbamate
-
Gabapentin
-
Humans
-
Infant
-
Lamotrigine
-
Oxcarbazepine
-
Phenylcarbamates
-
Propylene Glycols / therapeutic use
-
Triazines / therapeutic use
-
Vigabatrin
-
gamma-Aminobutyric Acid / analogs & derivatives
-
gamma-Aminobutyric Acid / therapeutic use
Substances
-
Acetates
-
Amines
-
Anticonvulsants
-
Cyclohexanecarboxylic Acids
-
Phenylcarbamates
-
Propylene Glycols
-
Triazines
-
Carbamazepine
-
gamma-Aminobutyric Acid
-
Gabapentin
-
Vigabatrin
-
Lamotrigine
-
Oxcarbazepine
-
Felbamate